Canada Consults On Disclosure Of Confidential Info On Approved Products
This article was originally published in Clinica
Executive Summary
Health Canada is seeking feedback on a draft guideline that explains how the health minister intends to use new discretionary powers to disclose confidential business information (CBI) about approved drugs and medical devices, without prior permission from affected companies, to help health researchers and practitioners in their work and to improve patient safety.